Core Insights - The 8th China International Import Expo (CIIE) commenced on November 5, showcasing Medtronic's commitment to "co-create the future of medical technology" with over a hundred innovative products and solutions, marking the largest exhibition area and product quantity in its history [1] - Medtronic views CIIE as a vital platform for deepening strategic partnerships and gathering local insights, emphasizing the importance of the Chinese market as a key driver for global medical technology innovation [2] - The company has introduced seven new products focused on the integration of artificial intelligence and healthcare, aiming to redefine future diagnosis and treatment pathways [2] - Medtronic has transitioned from being an exhibitor to an investor, establishing multiple core bases in China, including the NIM-ECLIPSE neuromonitoring system, which received approval in Japan and represents a model for "Made in China" products entering global markets [3] - The first digital healthcare innovation base in China was launched in Beijing, intended to connect Medtronic's global innovation capabilities with local partners [3] - Medtronic announced the initiation of a localized TAVR surgical AI solution, developed in collaboration with local doctors and AI companies, aiming to create a comprehensive treatment chain [3] Company Strategy - Medtronic's strategy focuses on "global wisdom localized, Chinese innovation globalized," leveraging the CIIE's influence to upgrade from an exhibitor to an investor and facilitating the transition of innovations from "imported" to "exported" [5] - The company aims to collaborate with partners in key areas such as digital healthcare and precision medicine to invigorate the Chinese medical market and explore the future of medical technology [5]